Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (07) : 662-666     DOI: 10.3971/j.issn.1000-8578.2022.21.1291
|
Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma
ZHOU Silei1, SUN Guanqun1*, ZENG Tanlun1, CHENG Zhuo2, LIANG Xijun1 (*: Contributed Equally as the First Author )
1. Clinical Cancer Institute, Center of Translational Medicine, Naval Medical University, Shanghai 200433, China; 2. Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200433, China
Download: PDF(5891 KB)   ( 38 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the expression of CK2α' in hepatocellular carcinoma (HCC) tissues and its prognosis value. Methods Tissue microarray was made from tumor and adjacent normal tissues of 83 patients with HCC. Immunohistochemical was used to stain the microarray for semi-quantitative analysis, and the expression of CK2α' in HCC tissues and adjacent normal tissues was compared. The associations between CK2α' expression and clinicopathologic features of HCC patients were analyzed with χ2 text. The prognostic value of CK2α' was estimated using Kaplan-Meier approach. Results The average positive expression rate of CK2α' was 47.8% in HCC and 65.4% in adjacent normal tissues. The positive expression rate of CK2α' in HCC tissues was lower than that in adjacent normal tissues (P<0.01). The expression level of CK2α' in the cancer tissues of 74.7% cases was significantly lower than that in the adjacent tissues. HCC patients with low CK2α' expression had higher risk of recurrence and shorter overall survival time (P<0.05). The expression of CK2α' was significantly correlated with CK19 (P<0.05). Conclusion CK2α' is down-regulated in HCC tissues and correlated with the prognosis of patients. It could be a potential prognostic marker for HCC.
Keywords CK2α'      Hepatocellular carcinoma      Prognosis     
ZTFLH:  R735.7  
  R73-3  
Fund:National Natural Science Foundation of China (No. 81801570)
Issue Date: 14 July 2022
 Cite this article:   
ZHOU Silei,SUN Guanqun,ZENG Tanlun, et al. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1291
http://www.zlfzyj.com/EN/Y2022/V49/I07/662
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
ZHOU Silei
SUN Guanqun
ZENG Tanlun
CHENG Zhuo
LIANG Xijun
[1] Liu Y, Veeraraghavan V, Pinkerton M, et al. Viral Biomarkers for
Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence
and Recurrence[J]. Front Microbiol, 2021, 12: 665201.
[2] Zhang Z, Chen P, Xie H, et al. Overexpr‍ession of GINS4 Is
Associated With Tumor Progression and Poor Survival in
Hepatocellular Carcinoma[J]. Front Oncol, 2021, 11: 654185.
[3] Borgo C, D’Amore C, Sarno S, et al. Protein kinase CK2: a potential therapeutic target for diverse human diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 183.
[4] Chua M, Lee M, Dominguez IM. Cancer-type dependent expr‍ession
of CK2 transcripts[J]. PLos One, 2017, 12(12): e0188854.
[5] Roffey SE, Litchfield DW. CK2 Regulation: Perspectives in
2021[J]. Biomedicines, 2021, 9(10): 1361.
[6] Seongrak K, Sunyoung H, Kyungmi Y, et al. Protein kinase CK2
activation is required for transforming growth factor-β-induced
epithelial-mesenchymal transition[J]. Mol Oncol, 2018, 12(10):
1811-1826.
[7] de Villavicencio-Diaz TN, Rabalski AJ, Litchfield DW. Protein
Kinase CK2: Intricate Relationships within Regulatory Cellular
Networks[J]. Pharmaceuticals (Basel) 2017, 10(1): 27.
[8] Pinna LA. Protein kinase CK2: a challenge to canons[J]. J Cell
Sci, 2002, 115(Pt 20): 3873-3878.
[9] Borgo C, Ruzzene M. Role of protein kinase CK2 in antitumor
drug resistance[J]. J Exp Clin Cancer Res, 2019, 38(1): 287.
[10] Dominguez I, Mizuno J, Wu H, et al. A role for CK2alpha/beta in
Xenopus early embryonic development[J]. Mol Cell Biochem,
2005, 274(1-2): 125-131.
[11] Dominguez I, Mizuno J, Wu H, et al. Protein kinase CK2 is
required for dorsal axis formation in Xenopus embryos[J]. Dev
Biol, 2004, 274(1): 110-124.
[12] Hong H, Benveniste EN. The Immune Regulatory Role of Protein
Kinase CK2 and Its Implications for Treatment of Cancer[J].
Biomedicines, 2021, 9(12): 1932.
[13] Channavajhala P, Seldin DC. Functional interaction of protein
kinase CK2 and c-Myc in lymphomagenesis[J]. Oncogene, 2002,
21(34): 5280-5288.
[14] Gomes AM, Soares MV, Ribeiro P, et al. Adult B-cell acute
lymphoblastic leukemia cells display decreased PTEN activity and
constitutive hyperactivation of PI3K/Akt pathway despite high
PTEN protein levels[J]. Haematologica, 2014, 99(6): 1062-1068.
[15] Storz MN, van de Rijn M, Kim YH, et al. Gene expr‍ession profiles
of cutaneous B cell lymphoma[J]. J Invest Dermatol, 2003,
120(5): 865-870.
[16] Lian H, Su M, Zhu Y, et al. Protein Kinase CK2, a Potential
Therapeutic Target in Carcinoma Management[J]. Asian Pac J
Cancer Prev, 2019, 20(1): 23-32.
[17] 安晓刚, 马万龙, 马玉, 等. 血清细胞角蛋白19检测在原发性肝癌中
的应用价值[J]. 宁夏医科大学学报, 2018, 40(2): 211-213. [An
XG, Ma WL, Ma Y, et al. Application value of serum cytokeratin
19 in primary liver cancer[J]. Ningxia Yi Ke Da Xue Xue Bao,
2018, 40(2): 211-213.]
[18] Chen Y, Chen J, Zhang Y, et al. Preoperative Prediction of
Cytokeratin 19 Expression for Hepatocellular Carcinoma with
Deep Learning Radiomics Based on Gadoxetic Acid-Enhanced
Magnetic Resonance Imaging[J]. J Hepatocell Carcinoma, 2021, 8:
795-808.
[19] Pi?ero F, Dirchwolf M, Pess?a MG. Biomarkers in Hepatocellular
Carcinoma: Diagnosis, Prognosis and Treatment Response
Assessment[J]. Cells, 2020, 9(6): 1370.
Related articles from Frontiers Journals
[1] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[2] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[3] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[4] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[5] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[6] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[7] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[8] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[9] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[10] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[11] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
[12] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[13] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[14] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
[15] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed